forpressrelease Mail to a Friend
forpressrelease Rate forpressrelease forpressrelease forpressrelease forpressrelease forpressrelease 

Erythropoietin Biosimilars Open Array of Opportunity for Market Growth



2024-03-28 03:50:51 Industry

forpressrelease
1225


?A strong pipeline of Erythropoietin Biosimilars is offering significant growth opportunities for the Global Erythropoietin Market?, says RNCOS.

Biosimilars have been developed for several biologic therapeutic agents, including erythropoiesis-stimulating agents. These erythropoietin biosimilars are biopharmaceutical drugs that are designed to have properties which are similar to the ones of biologic erythropoietin. Since the year of their introduction, these erythropoietin biosimilars have gained a lot of popularity. The biologic erythropoietins are more complex and costly to develop, whereas the biosimilars being the generic version of these biologics are a cost-effective alternative to these high priced drugs. The biosimilar erythropoietin cost about 25% less than the innovator drug, due to the reduced clinical trials. This results in higher adoption rate of these biosimilar erythropoietin drugs as compared to innovators.

According to ?EPO Biosimilars - The Future of Erythropoietin Market? currently, there are numerous biosimilar erythropoietin drugs in various stages of clinical trials for the treatment of anemia caused due to various diseases. These trials are being carried out so that the therapeutic ability of these biosimilar erythropoietin drugs can be gauged. Some trials focus on newly developed erythropoietin biosimilar drugs whereas others try to check the efficacy of previously approved drugs, such as HX575, for other indications.

The major players operating in erythropoietin market are Amgen, Johnson & Johnson, and Roche, among others. Apart from these, there are many new entrants in this field, like Kyowa Hakko Kirin, SIAM Bioscience, XTL Biopharmaceuticals Ltd. and Pooyesh Darou Biopharmaceutical Co., who are contributing significantly in the field of anemia treatment by developing new erythropoietin biosimilar options for patients. The erythropoietin biosimilars in various stages of clinical development are KRN321, JR-131, NuPIAO, PEG-EPO, JR-131, and ErepoXen, among others. The strong pipeline of these erythropoietin biosimilars is poised to drive the growth of the global erythropoietin market in the coming years.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM851.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

ABOUT RNCOS

RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.

Company :-RNCOS E-Services Pvt. Ltd.

User :- Shushmul Maheshwari

Email :-press@rncos.com

Phone :-24700-24700-4224700

Mobile:- 120-4224700

Url :- http://www.rncos.com






Related Post